Breaking News Instant updates and real-time market news.

GOOG

Alphabet

$777.29

2.28 (0.29%)

, GOOGL

Alphabet Class A

$804.06

1.42 (0.18%)

13:46
10/02/16
10/02
13:46
10/02/16
13:46

Google, Facebook ad dominance could eventually end, Barron's says

Alphabet (GOOG) and Facebook (FB) could eventually lose their dominance in online advertising as new platforms and ad paradigms enter the market, Barron's says in a 'Technology Trader' column, citing Wedbush analyst James Dix's downgrade of Google last week. It is "probably too soon" to say Google is in trouble given its sheer momentum in the space, but change can happen, and it is not too soon to start considering the implications, Barron's adds. Reference Link

GOOG

Alphabet

$777.29

2.28 (0.29%)

GOOGL

Alphabet Class A

$804.06

1.42 (0.18%)

FB

Facebook

$128.27

0.18 (0.14%)

  • 23

    Oct

  • 27

    Oct

  • 15

    Jan

GOOG Alphabet
$777.29

2.28 (0.29%)

09/28/16
09/28/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Alphabet (GOOG, GOOGL) downgraded to Underperform from Neutral at Wedbush with analyst James Dix citing concerns that the "Four Horsemen of the Search Apocalypse" -- self-identified consumers, consumer control of IP-delivered ads, payments innovation, and attention markets -- might arrive. 2. AT&T (T) downgraded to Neutral from Buy at UBS with analyst John Hodulik citing expectations for lower earnings growth. 3. Macy's (M) downgraded to Neutral from Outperform at Credit Suisse with analyst Michael Exstein saying the retailer, after outlining in August its operations and merchandising strategies, is now in an execution phase. 4. Twitter (TWTR) downgraded to Underperform from Neutral at Mizuho and to Sell from Hold at Loop Capital. 5. Galectin Therapeutics (GALT) downgraded to Sell from Buy at Roth Capital with analyst Sa'ar Yaniv citing the company's announcement that NASH-FX, GR-MD-02's Phase 2a study in NASH fibrosis, failed both primary and secondary endpoints. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/28/16
MZHO
09/28/16
DOWNGRADE
Target $15
MZHO
Underperform
Mizuho cuts Twitter to Underperform with $15 price target
Mizuho analyst Neil Doshi downgraded Twitter to Underperform from Neutral based on valuation. The shares are up 45% since the company reported Q2 results, primarily driven by potential buyout comments in media reports, Doshi tells investors in a research note. The stock at current levels is overvalued as Twitter's business fundamentals "have deteriorated significantly" over the past 12 months, the analyst contends. Doshi believes many of the M&A scenarios are unlikely to play out. He puts potential acquirers Salesforce (CRM) and Alphabet (GOOG, GOOGL) in the "maybe" camp, but he still has some reservations about these deals happening. The analyst believes investors of both companies would view a buyout of Twitter as negative. Doshi keeps a $15 price target for Twitter shares. The stock closed yesterday up 35c to $23.72. Loop Capital this morning also downgraded Twitter to Sell.
09/27/16
WEDB
09/27/16
DOWNGRADE
WEDB
Underperform
Alphabet downgraded to Underperform from Neutral at Wedbush
Wedbush analyst James Dix downgraded Alphabet to Underperform and lowered his price target on shares to $700 on concerns the "Four Horsemen of the Search Apocalypse" -- self-identified consumers, consumer control of IP-delivered ads, payments innovation, and attention markets -- might arrive.
09/27/16
WEDB
09/27/16
DOWNGRADE
WEDB
Underperform
Alphabet downgraded to Underperform from Neutral at Wedbush
GOOGL Alphabet Class A
$804.06

1.42 (0.18%)

09/30/16
RBCM
09/30/16
NO CHANGE
RBCM
Street underestimating Google growth outlook, says RBC Capital
RBC Capital analyst Mark Mahaney expects Google to end 2016 with "up to 20% growth," versus the Street's outlook of mid teen percentage level growth. Mahaney says that Google's growth should be boosted by "ongoing Search innovations, rising Mobile CPCs, and the growing impact of YouTube, Play & Cloud." He thinks that YouTube's revenue is growing at a 30%-40% clip. Mahaney raised his price target on the stock to $1,025 from $1,000 and keeps an Outperform rating on the shares.
FB Facebook
$128.27

0.18 (0.14%)

09/30/16
ROTH
09/30/16
NO CHANGE
ROTH
Buy
Facebook video measurement gaffe has no impact on MeetMe, says Roth Capital
Roth Capital analyst Darren Aftahi noted that recent bear reports, including one that surfaced yesterday, regarding MeetMe (MEET) contend that the company could be negatively impacted by spillover from Facebook's (FB) admission that it had been overstating time spent by its users watching video on its platform, but he does not expect Facebook's issue to have any impact on MeetMe. He also said that, contrary to bear assertions of bad reviews, MeetMe's app scores well relative to Tinder and Snapchat. The analyst keeps a Buy rating on MeetMe and sees pullbacks following short reports as buying opportunities.
09/27/16
JPMS
09/27/16
NO CHANGE
Target $175
JPMS
Overweight
Facebook price target raised to $175 from $170 at JPMorgan
JPMorgan analyst Doug Anmuth raised his price target for Facebook to $175 on a roll forward to his 2017 estimates. The analyst keeps an Overweight rating on the shares. The target is for December 2017.
09/26/16
CANT
09/26/16
NO CHANGE
Target $42
CANT
Buy
Yelp takeout chances increased with share conversion, says Cantor
Yelp's (YELP) conversion of Class B super-voting shares into regular Class A shares late last week increases the company's takeout potential, Cantor Fitzgerald analyst Youssef Squali tells investors in a research note. Yelp, especially following recent improvements in the underlying growth fundamentals of the business, has become "an easier, and more likely" acquisition target, the analyst contends. The analyst views Facebook (FB), Priceline (PCLN), TripAdvisor (TRIP) and Microsoft (MSFT) as potential acquirers of Yelp. Squali estimates Yelp could be worth $53 per share in a takeout. He keeps a Buy rating on the stock with a $42 price target. The stock is up 2% to $40.35 in early trading.
09/26/16
RHCO
09/26/16
NO CHANGE
RHCO
Facebook inaccurate average video viewing times immaterial, says SunTrust
SunTrust analyst Robert Peck does not believe that Facebook's overstatement of average video viewing times is significant. The analyst says that the metric does not affect budgets and ROI, while Facebook "was quick and open about the issue." He thinks that the website's reach makes it "a must buy for advertisers." Peck keeps a Buy rating on the stock.

TODAY'S FREE FLY STORIES

CELG

Celgene

$117.63

-1.24 (-1.04%)

19:27
12/04/16
12/04
19:27
12/04/16
19:27
Hot Stocks
Acetylon reports initial Phase 1a/b data for citarinostat in myeloma »

Acetylon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

XLRN

Acceleron

$36.29

1.25 (3.57%)

, CELG

Celgene

$117.63

-1.24 (-1.04%)

19:23
12/04/16
12/04
19:23
12/04/16
19:23
Hot Stocks
Acceleron, Celgene report updated data from Phase 2 luspatercept studies »

Acceleron Pharma (XLRN)…

XLRN

Acceleron

$36.29

1.25 (3.57%)

CELG

Celgene

$117.63

-1.24 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 04

    Dec

  • 05

    Dec

  • 06

    Dec

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

19:05
12/04/16
12/04
19:05
12/04/16
19:05
Hot Stocks
Alnylam reports Phase 2 data on fitusiran in hemophilia »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$122.96

0.95 (0.78%)

19:01
12/04/16
12/04
19:01
12/04/16
19:01
Hot Stocks
Alexion reports data from Phase 1/2 ALXN1210 study »

Alexion Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 14

    Dec

LYV

Live Nation

$27.07

-0.44 (-1.60%)

18:58
12/04/16
12/04
18:58
12/04/16
18:58
Hot Stocks
Live Nation acquires 51% stake in Australia's Secret Sounds Group »

Live Nation Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$68.17

0.42 (0.62%)

18:45
12/04/16
12/04
18:45
12/04/16
18:45
Hot Stocks
Novartis reports Phase 2 data on CTL019 in leukemia »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

ABBV

AbbVie

$59.43

0.27 (0.46%)

, JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

18:29
12/04/16
12/04
18:29
12/04/16
18:29
Hot Stocks
AbbVie reports five-year IMBRUVICA data, updated RESONATE-2 data »

AbbVie (ABBV) announced…

ABBV

AbbVie

$59.43

0.27 (0.46%)

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

CELG

Celgene

$117.63

-1.24 (-1.04%)

18:17
12/04/16
12/04
18:17
12/04/16
18:17
Hot Stocks
Celgene, Dana-Farber, U of Arkansas form Myeloma Genome Project »

Celgene, Dana-Farber…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

ARQL

ArQule

$1.37

-0.01 (-0.72%)

18:12
12/04/16
12/04
18:12
12/04/16
18:12
Hot Stocks
ArQule reports data presentation on ARQ 092 in sickle cell disease »

ArQule announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$98.50

-0.44 (-0.44%)

, TWX

Time Warner

$93.80

-0.34 (-0.36%)

18:08
12/04/16
12/04
18:08
12/04/16
18:08
Hot Stocks
Box Office Battle: 'Moana,' 'Fantastic Beasts' win post-Thanksgiving weekend »

Disney's (DIS)…

DIS

Disney

$98.50

-0.44 (-0.44%)

TWX

Time Warner

$93.80

-0.34 (-0.36%)

VIA

Viacom

$40.35

-1 (-2.42%)

VIAB

Viacom

$36.52

-0.74 (-1.99%)

SNE

Sony

$28.06

-0.16 (-0.57%)

FOX

21st Century Fox

$27.37

-0.71 (-2.53%)

FOXA

21st Century Fox

$27.40

-0.8 (-2.84%)

LGF

Lionsgate

$22.72

0.02 (0.09%)

CMCSA

Comcast

$68.78

-1.08 (-1.55%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SBUX

Starbucks

$57.21

-1.3 (-2.22%)

17:09
12/04/16
12/04
17:09
12/04/16
17:09
Conference/Events
Starbucks to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

CS

Credit Suisse

$13.39

-0.34 (-2.48%)

17:03
12/04/16
12/04
17:03
12/04/16
17:03
Conference/Events
Credit Suisse to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 14

    Dec

TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.40

0.135 (0.67%)

, SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

17:02
12/04/16
12/04
17:02
12/04/16
17:02
Hot Stocks
Takeda Pharma, Seattle Genetics reports Phase 3 ADCETRIS data »

Takeda Pharmaceutical…

TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.40

0.135 (0.67%)

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

CGEN

Compugen

$5.95

0.1 (1.71%)

16:59
12/04/16
12/04
16:59
12/04/16
16:59
Conference/Events
Compugen to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

QURE

uniQure

$5.68

-0.31 (-5.18%)

16:56
12/04/16
12/04
16:56
12/04/16
16:56
Hot Stocks
uniQure reports data on AMT-060 in hemophilia B »

uniQure announced new and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 08

    Dec

RGLS

Regulus

$2.50

0.1 (4.17%)

16:53
12/04/16
12/04
16:53
12/04/16
16:53
Conference/Events
Regulus to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 14

    Dec

PBI

Pitney Bowes

$14.63

0.1 (0.69%)

16:52
12/04/16
12/04
16:52
12/04/16
16:52
Conference/Events
Pitney Bowes to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

16:43
12/04/16
12/04
16:43
12/04/16
16:43
Hot Stocks
Seattle Genetics reports Phase 1b vadastuximab talirine data, plans Ph. 2 trial »

Seattle Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

NVS

Novartis

$68.17

0.42 (0.62%)

16:38
12/04/16
12/04
16:38
12/04/16
16:38
Hot Stocks
Novartis reports Phase 2 SEG101 data »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

PFE

Pfizer

$31.63

0.17 (0.54%)

16:33
12/04/16
12/04
16:33
12/04/16
16:33
Hot Stocks
Pfizer reports Phase 2 glasdegib data »

Pfizer announced new data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

EKSO

Ekso Bionics

$4.27

-0.11 (-2.51%)

16:30
12/04/16
12/04
16:30
12/04/16
16:30
Conference/Events
Ekso Bionics to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

ADSK

Autodesk

$70.57

1.35 (1.95%)

16:24
12/04/16
12/04
16:24
12/04/16
16:24
Conference/Events
Autodesk to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

  • 09

    Jan

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

16:23
12/04/16
12/04
16:23
12/04/16
16:23
Hot Stocks
Seattle Genetics reports Phase 2 ADCETRIS lymphoma data, says discontinues trial »

Seattle Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

FTI

FMC Technologies

$35.60

0.9 (2.59%)

, TKPPY

Technip

$17.80

0.45 (2.59%)

16:21
12/04/16
12/04
16:21
12/04/16
16:21
Conference/Events
Technip to host special shareholder meeting »

Special Shareholder…

FTI

FMC Technologies

$35.60

0.9 (2.59%)

TKPPY

Technip

$17.80

0.45 (2.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

TKPPY

Technip

$17.80

0.45 (2.59%)

, FTI

FMC Technologies

$35.60

0.9 (2.59%)

16:14
12/04/16
12/04
16:14
12/04/16
16:14
Conference/Events
FMC Technologies to host special shareholder meeting »

Special Shareholder…

TKPPY

Technip

$17.80

0.45 (2.59%)

FTI

FMC Technologies

$35.60

0.9 (2.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.